3 November 2020 - Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study
et al., PLoS ONE, doi:10.1371/journal.pone.0247163 (preprint 11/3) (Peer Reviewed)
Retrospective matched case-control prophylaxis study for HCQ, ivermectin, and vitamin C with 372 healthcare workers, showing lower COVID-19 incidence for all treatments, with statistical significance reached for ivermectin.HCQ OR 0.56, p = 0.29
Ivermectin OR 0.27, p < 0.001
Vitamin C OR 0.82, p = 0.58
Ivermectin OR 0.27, p < 0.001
Vitamin C OR 0.82, p = 0.58
|
risk of case, 27.9% lower, RR 0.72, p = 0.29, treatment 7 of 19 (36.8%), control 179 of 353 (50.7%), NNT 7.2, adjusted per study, odds ratio converted to relative risk, model 2 conditional logistic regression.
|
|
risk of case, 26.3% lower, RR 0.74, p = 0.25, treatment 7 of 19 (36.8%), control 179 of 353 (50.7%), NNT 7.2, odds ratio converted to relative risk, matched pair analysis.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Behera et al., 11/3/2020, retrospective, India, South Asia, peer-reviewed, 13 authors.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.